✦ LIBER ✦

Interferon-Β-1a: `Rebif' superior to `Avonex' for relapsing-remitting MS

Book ID: 120859327
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2003
Weight: 134 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200313900-00027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The interferon-β-1a product `Rebif' may

The interferon-β-1a product `Rebif' may have advantages in relapsing-remitting MS

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Alemtuzumab superior to IFN-β-1a for rel

Alemtuzumab superior to IFN-β-1a for relapsing-remitting MS

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Interferon-β-1a effective in relapsing-r

Interferon-β-1a effective in relapsing-remitting MS

📂 Article 📅 1997 🏛 Adis International Limited (now part of Wolters Kl ⚖ 284 KB

Physiological measures of therapeutic re

Physiological measures of therapeutic response to interferon beta-1a treatment in remitting–relapsing MS

✍ Andrea T. White; Jack H. Petajan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 200 KB

Extended observations on MS patients tre

Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics

✍ Lawrence Jacobs; Richard Rudick; Jack Simon 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Extended observations on MS patients tre

Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics

✍ Lawrence Jacobs; Richard Rudick; Jack Simon 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Extended observations of the pivotal phase III clinical trial of interferon-beta1a (IFNbeta1a; Avonex, Biogen) in relapsing MS patients revealed that: (1) active treatment significantly slowed the accumulation of physical disability over time, reduced clinical exacerbations and MRI brain lesions; (2